Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept treat-and-extend for diabetic macular edema in an outpatient regional care network
2015-000959-24Phase 4Completed
- Sponsor
- Department of Ophthalmology, Kepler University Hospital
- Start
- Jul 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Department of Ophthalmology, Kepler University Hospital. Primary endpoint: Visual acuity achieved. Started Jul 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2015-000959-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000959-24.